
<DOC>
<DOCNO>WT01-B04-7</DOCNO>
<DOCOLDNO>IA046-000815-B033-308</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3_1.htm 205.178.27.23 19970119003102 text/html 17135
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:34:14 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 16 Oct 1996 22:20:45 GMT
Content-Length: 16936
</DOCHDR>
<!--This file created 10/16/96 3:20 PM by Claris Home Page version 1.0-->
<HTML>
<HEAD>
   <TITLE>Generic Anticancer Pharmaceuticals</TITLE>
   <META NAME=GENERATOR CONTENT="Claris Home Page 1.0">
   <X-SAS-WINDOW TOP=48 BOTTOM=624 LEFT=59 RIGHT=730>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP>
</P>

<P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=550>
   <TR>
      <TD>
         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136
         BORDER=0 ALIGN=left usemap="#newnav">
      </TD></TR>
   <TR>
      <TD VALIGN=top>
         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"><AREA SHAPE=rect COORDS="30,85,88,96" HREF="2_3.htm"></MAP>
         </P>
         
         <P><IMG SRC="images/2_3_1.gif" WIDTH=472 HEIGHT=117 BORDER=0
         ALIGN=left usemap="#2">
      </TD></TR>
</TABLE></P>

<P><TABLE BORDER=0 CELLPADDING=1 WIDTH=623>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>The Company currently has four
         generic drugs cleared for the U.S. market, and also is
         waiting to receive clearance for its generic version of
         mitomycin. Five other generic drugs currently are in
         development. The Company believes that early
         commercialization of its generic drugs will assist it in
         developing its reputation and presence in the market while
         it continues to develop its supergeneric and proprietary
         products.</FONT></P>
         
         <P><FONT SIZE=4>Generic drugs currently being marketed by
         SuperGen are as follows<A NAME="pent"></A>:</FONT></P>
         
         <P>&nbsp;</BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">P</FONT></B><FONT SIZE=5 COLOR="#232B68">entostatin</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Pentostatin is indicated for the
         treatment of hairy cell leukemia, for which it has been
         granted Orphan Drug status in the U.S. Orphan Drug status
         also has been granted for its use in chronic lymphocytic
         leukemia. The total U.S. market for these two diseases is
         estimated at </FONT><B><FONT SIZE=4>$65 million for
         1996.</FONT></B><FONT SIZE=4> While the patent for the drug
         has expired, SuperGen's exclusive rights are protected by
         Orphan Drug status until October,
         1998<A NAME="meth"></A>.</FONT></BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">ethotrexate</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Methotrexate, manufactured for
         SuperGen under a license from Barr Laboratories, is used in
         the treatment of leukemias, lymphomas, breast cancer, head
         and neck cancer. Estimated U.S. sales of Methotrexate were
         approximately </FONT><B><FONT SIZE=4>$70 million in 1995 and
         $78.5 million in 1994<A NAME="mege"></A>.</FONT></B>
         </BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">egestrol</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P><FONT SIZE=5 COLOR="#232B68">Acetate</FONT>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Megestrol acetate, manufactured
         for SuperGen under a license from Barr Laboratories, is
         indicated for the palliative treatment of advanced carcinoma
         of the breast and endometrium, with an estimated U.S. market
         of </FONT><B><FONT SIZE=4>$39 million in 1995 and $35
         million in 1994<A NAME="leuc"></A>.</FONT></B></BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">L</FONT></B><FONT SIZE=5 COLOR="#232B68">eucovorin</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P><FONT SIZE=5 COLOR="#232B68">Calcium</FONT>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Leucovorin calcium, manufactured
         for SuperGen under a license from Barr Laboratories in two
         different tablet dosage forms, is used as a rescue treatment
         for high dose methotrexate therapy. The estimated U.S.
         market for this drug was approximately
         </FONT><B><FONT SIZE=4>$9 million in 1995 and also in
         1994.</FONT></B></P>
         
         <P><FONT SIZE=4>&nbsp;</FONT></P>
         
         <P><FONT SIZE=4>The Company's generic drugs currently under
         development are as follows<A NAME="mito"></A>:</FONT>
         </BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">itomycin</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=295 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Mitomycin, with estimated sales
         in the U.S. of approximately </FONT><B><FONT SIZE=4>$36.4
         million in 1995 and $41.5 million in
         1994</FONT></B><FONT SIZE=4>, is indicated for gastric and
         pancreatic carcinoma. The patent for mitomycin expired in
         1987, and as of December 31, 1995 only one generic version
         of mitomycin had been approved for commercial sale in
         addition to the original version produced by Bristol-Myers
         Squibb<A NAME="cisp"></A>.</FONT></BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">C</FONT></B><FONT SIZE=5 COLOR="#232B68">isplatin</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=190 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Cisplatin is indicated for the
         treatment of metastatic testicular tumors, metastatic
         ovarian tumors, and advanced bladder cancer. Sales of
         Cisplatin in the U.S. were estimated to be approximately
         </FONT><B><FONT SIZE=4>$41.4 million in 1995 and $42.4
         million in 1994</FONT></B><FONT SIZE=4>. A patent for
         cisplatin is expiring in December, 1996. Therefore, no
         generic versions of Cisplatin have been approved for
         commercial sale to date.<A NAME="etop"></A>. </FONT>
         </BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">E</FONT></B><FONT SIZE=5 COLOR="#232B68">toposide</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=190 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>In combination with other
         chemotherapeutic agents, etoposide is indicated for the
         management of refractory testicular tumors and small cell
         lung cancer. Sales of Etoposide in the U.S. were estimated
         to be </FONT><B><FONT SIZE=4>$104.9 million in 1995 and
         $140.9 million in 1994.</FONT></B><FONT SIZE=4> The patent
         for Etoposide expired in November 1993. There are currently
         three generic versions of Etoposide that have been approved
         for commercial sale, in addition to the original version
         produced by Bristol Myers-Squibb<A NAME="vinc"></A>. </FONT>
         </BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">V</FONT></B><FONT SIZE=5 COLOR="#232B68">incristine</FONT>
      
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=85 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Vincristine is used to treat
         Hodgkin's disease, lymphomas, acute leukemia,
         rhabdomyosarcoma, neuroblastoma, and Wilm's tumor. Sales of
         Vincristine in the U.S. were estimated to be approximately
         </FONT><B><FONT SIZE=4>$5.8 million in 1995 and $7.9 million
         in 1994.</FONT></B><FONT SIZE=4> The patent for Vincristine
         expired in 1982 and there are other generic versions of
         Vincristine that have been approved for commercial sale, in
         addition to the original version produced by Eli Lilly and
         Company<A NAME="vinb"></A>. </FONT></BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><FONT SIZE=5 COLOR="#232B68">Vinblastine</FONT>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=85 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Vinblastine is indicated for the
         palliative treatment of generalized Hodgkin's disease
         (Stages III and IV) and Kaposi's sarcoma. Estimated U.S.
         sales currently are approximately </FONT><B><FONT SIZE=4>$2
         million</FONT></B><FONT SIZE=4><A NAME="bleo"></A>.</FONT>
         </BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P>
      </TD><TD COLSPAN=5>
         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=2>
         <P><FONT SIZE=5 COLOR="#232B68">Bleomycin</FONT>
      </TD><TD COLSPAN=5>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=7>
         <BLOCKQUOTE><P><FONT SIZE=4>Bleomycin is indicated for
         palliative treatment in the management of squamous cell
         carcinoma of the head and neck, Hodgkin's disease, reticulum
         cell sarcoma, lymphosarcoma, and testicular carcinoma. Sales
         of bleomycin in the U.S. were estimated to be
         approximately</FONT><B><FONT SIZE=4> $43.5 million in 1995
         and $43.5 million in 1994.</FONT></B><FONT SIZE=4> The
         patent for bleomycin expired in 1989 and one generic version
         has been approved for commercial sale to date.</FONT>
         </BLOCKQUOTE>
      </TD></TR>
</TABLE></P>

<P>&nbsp;</P>

<P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMG
SRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottom
usemap="#lowNAV"></P>
</BODY>
</HTML>
</DOC>